Severe cases of persistent corneal injury have been reported when similar products have accidentally come into contact with the eyes during surgical interventions, in patients under general anesthesia (deep, painless sleep).
Do not use in case of deep and extensive wounds.
In case of repeated applications, applications on very extensive areas, or when using dressings that cover the affected area, it may favor the product penetrating through the skin and producing unwanted effects.
Clothing that has come into contact with Hibiscrub should not be washed with bleach or other hypochlorites, as this would cause a brownish discoloration of the tissues, but with domestic detergents based on sodium perborate.
Use with caution in newborns, especially in premature children. Hibiscrub may cause chemical burns on the skin.
Hibiscrub is flammable. Do not use it near ignition sources until it is dry.
Niños y pacientes de edad avanzada
No hay recomendaciones especiales de dosificación para niños y pacientes de edad avanzada. La dosis normal de adultos es apropiada a menos que se recomiende otra por el médico.
Otros medicamentos y Hibiscrub
Informe a su médico o farmacéutico si está utilizando, ha utilizado recientemente o pudiera tener que utilizar cualquier otro medicamento.
Debe evitarse utilizar varios desinfectantes a la vez o de forma sucesiva, salvo con otros compuestos catiónicos.
No debe usarse en combinación ni después de la aplicación de jabones aniónicos, ácidos, sales de metales pesados y yodo.
Embarazo, lactancia y fertilidad
Si está embarazada o en periodo de lactancia, cree que podría estar embarazada o tiene intención de quedarse embarazada, consulte a su médico o farmacéutico antes de utilizar este medicamento.
No existe evidencia de efectos adversos sobre el feto derivados del uso de este medicamento para el lavado de manos durante el embarazo y la lactancia.
Conducción y uso de máquinas
No se han descrito efectos sobre la capacidad de conducción y uso de máquinas tras el uso de este medicamento.
Hibiscrubcontiene alcohol isopropílico y perfume cítrico
This medication contains 40 mg of isopropyl alcohol in each ml. It may cause dryness, irritation, redness, or burning sensation on the skin. Contact dermatitis or allergic contact dermatitis are very rare.
This medication contains fragrances with 3-Methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, Amilcinamaldehyde, Isopropyl amylcinamaldehyde, Anisyl alcohol, Benzyl alcohol, Benzoate of benzyl, Cinnamate of benzyl, Salicylate of benzyl, Cinnamaldehyde, Isopropyl cinnamyl alcohol, Citral, Citronellol, Coumarin, d-Limonene, Eugenol, Farnesol, Geraniol, Hexyl cinnamaldehyde, Hydroxycitronellal, Hydroxymethylpentyl-cyclohexenecarboxaldehyde, Isoeugenol, Lilial, Linalool, Methyl heptine carbonate, Extract of red cedar moss, and Extract of red cedar moss. These may cause allergic reactions.
The fragrance also contains Bergamot oil containing bergapten, Soy oil, Ethanol, Methyl benzoate, Benzoic acid, Peru balsam, Formaldehyde, and Sodium lauryl sulfate.
Bergamot oil containing bergapten may increase sensitivity to UV light (natural or artificial daylight).
Etanol may cause a burning sensation on injured skin.
Benzoic acid, Benzyl benzoate, and Methyl benzoate may cause local irritation. Benzoic acid, Benzyl benzoate, and Methyl benzoate may increase the risk of jaundice (yellow discoloration of the skin and eyes) in newborns (up to 4 weeks of age).
Peru balsam may cause skin reactions.
Formaldehyde may cause local skin reactions (such as contact dermatitis).
Sodium lauryl sulfate may cause local skin reactions (such as itching or burning sensation) or increase skin reactions caused by other medications when applied to the same area.
3. How to use Hibiscrub
Follow exactly the administration instructions of the medication contained in this leaflet or those indicated by your doctor or pharmacist. In case of doubt, ask your doctor or pharmacist.
Skin use.
Surgical hand antisepsis:
Moisten hands and forearms, apply 5 ml of Hibiscrub and wash for 1 minute, cleaning nails with a brush, rinse and apply another 5 ml for 2 minutes; rinse and dry.
Antisepsis hand washing for healthcare personnel:
Moisten hands and forearms, apply 5 ml of Hibiscrub and wash for 1 minute; rinse and dry.
Pre-operative skin antisepsis:
Bathe the entire body (bath or shower) at least 2 times, usually the day before and the day of the operation as follows: the day before the operation, wash with 25 ml of Hibiscrub from the face downwards, paying attention to the surrounding areas of the nose, armpits, navel, groin, and perineum. Then rinse and repeat the wash with another 25 ml, including the hair. Finally, rinse and dry. This procedure will be repeated the next day. For bedridden patients, apply the usual bed washing technique. Perform the conventional antisepsis of the surgical area with the patient in the operating room.
Post-operative skin antisepsis:
From the third day of the surgical procedure, bathe the entire body, excluding the surgical area, following the pre-operative skin antisepsis washing procedure.
If you use more Hibiscrub than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
Unknown frequency (cannot be estimated from available data):
Severe allergic reactions (anaphylactic reaction) that may cause breathing difficulty, weakness, collapse, and death, and in some cases may be preceded by swelling (particularly lip, tongue, and facial swelling) or rash.
Chemical burns in newborns.
At the first signs of these reactions, report to your doctor, pharmacist, or nurse and immediately discontinue the application of Hibiscrub..
Other possible adverse effects are:
Unknown frequency (cannot be estimated from available data): skin allergic disorders, skin inflammation (dermatitis), itching (pruritus), skin redness (erythema), eczema, rash, urticaria (hives), skin irritation, and blisters.
Corneal lesions (surface eye damage) and permanent eye damage, including permanent visual deterioration (following accidental eye exposure during surgical interventions on the head, face, and neck) in patients under general anesthesia (induced painless deep sleep).
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicinal Products for Human Use: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
5. Hibiscrub Storage
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the bottle after 'CAD'. The expiration date is the last day of the month indicated.
Do not store at a temperature above 25°C.
Medicines should not be disposed of through drains or in the trash. Dispose of containers and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of containers and medications you no longer need. By doing so, you will help protect the environment.
6. Contents of the packaging and additional information
Composition of Hibiscrub
The active ingredient is chlorhexidine digluconate. Each ml contains 40 mg of chlorhexidine digluconate.
The other components (excipients) are: PEG-7-glyceril cocoate, glycerol (E422), D-gluconolactone, isopropyl alcohol, laurildimethylamine oxide, citrus perfume, poloxamer 237 (copolymer of polyoxyethylene-polyoxypropylene), Ponceau 4R (E124), sodium hydroxide (E524), and purified water.
Appearance of the product and contents of the packaging
Hibiscrub is presented in 500 ml HPDE bottles.
Marketing Authorization Holder
Mölnlycke Health Care AB
Entreprenörsstråket 21
SE-431 53 Mölndal
Sweden
Responsible for Manufacturing
Société de Production Pharmaceutique et d'Hygiène (SPPH)
7 Impasse des Boussenots
21800 Quetigny
France
Local Representative
Mölnlycke Healthcare, S.L.
Last review date of this leaflet: June 2024
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Glicerol (e 422) (0,03 g mg),
Rojo ponceau 4r (ci=16255, e-124) (0,00005 g mg)
Информация носит справочный характер и не является медицинской рекомендацией. Перед приёмом любых препаратов проконсультируйтесь с врачом. Oladoctor не несёт ответственности за медицинские решения, принятые на основе этого контента.
Поговоріть з лікарем онлайн
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.